TP53 and acute myeloid leukemia: The presence of a pathogenic TP53 mutation at a variant allele frequency (VAF) of ≥10% defines AML with mutated TP53 (TP53m AML), a subgroup classified as adverse risk based on the European LeukemiaNet (ELN)’s classification [2].